NASDAQ: VOR

Vor Biopharma Inc Stock Forecast, Predictions & Price Target

The consensus among 5 Wall Street analysts covering (NASDAQ: VOR) stock is to Buy VOR stock.

Out of 5 analysts, 1 (20%) are recommending VOR as a Strong Buy, 4 (80%) are recommending VOR as a Buy, 0 (0%) are recommending VOR as a Hold, 0 (0%) are recommending VOR as a Sell, and 0 (0%) are recommending VOR as a Strong Sell.

If you're new to stock investing, here's how to buy Vor Biopharma stock.

(NASDAQ: VOR) Vor Biopharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.92%.

Vor Biopharma's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast VOR's revenue for 2025 to be $681,687,710, with the lowest VOR revenue forecast at $681,687,710, and the highest VOR revenue forecast at $681,687,710. On average, 1 Wall Street analysts forecast VOR's revenue for 2026 to be $3,408,438,550, with the lowest VOR revenue forecast at $3,408,438,550, and the highest VOR revenue forecast at $3,408,438,550.

In 2027, VOR is forecast to generate $3,545,662,286 in revenue, with the lowest revenue forecast at $595,113,371 and the highest revenue forecast at $6,633,503,106.

According to 5 Wall Street analysts that have issued a 1 year VOR price target, the average VOR price target is $13.50, with the highest VOR stock price forecast at $17.50 and the lowest VOR stock price forecast at $11.00.

On average, Wall Street analysts predict that Vor Biopharma's share price could reach $13.50 by Apr 23, 2025. The average Vor Biopharma stock price prediction forecasts a potential upside of 694.12% from the current VOR share price of $1.70.

(NASDAQ: VOR) forecast ROE is N/A, which is considered weak.